Robust Call Option Volumes Signal Investor Optimism
The pharmaceutical heavyweight Cipla Ltd (NSE: CIPLA) has emerged as one of the most actively traded stocks in the call options segment this week. Data from the derivatives market reveals that call options with strike prices of ₹1,300 and ₹1,400 expiring on 26 May 2026 have attracted significant interest. Specifically, the ₹1,400 strike call options recorded 19,553 contracts traded, generating a turnover of approximately ₹675.31 lakhs, while the ₹1,300 strike calls saw 15,813 contracts traded with a turnover of ₹2,507.15 lakhs.
This heightened activity is underscored by open interest figures, with the ₹1,400 strike calls holding an open interest of 3,656 contracts and the ₹1,300 strike calls at 1,118 contracts. The underlying stock price stood at ₹1,342 on 13 May 2026, positioning the ₹1,400 strike calls slightly out-of-the-money, which suggests traders are positioning for a potential upside move in the near term.
Price Action and Technical Indicators Support Bullish Positioning
On the equity front, Cipla outperformed its sector by 3.5% on 13 May, registering a 4.38% gain for the day and touching an intraday high of ₹1,353.8. This rebound follows a four-day consecutive decline, indicating a possible trend reversal. The stock’s weighted average traded price skewed closer to the day’s low, reflecting some profit booking but sustained buying interest.
Technically, Cipla’s price remains above its 5-day, 20-day, and 50-day moving averages, signalling short- to medium-term strength. However, it still trades below its 100-day and 200-day moving averages, suggesting that longer-term momentum remains cautious. Rising delivery volumes, which increased by 4.93% to 7.54 lakh shares on 12 May compared to the five-day average, further confirm growing investor participation.
Mojo Score and Market Capitalisation Context
Despite the bullish option activity and positive price action, Cipla’s Mojo Score currently stands at 41.0, categorised as a Sell grade as of 7 January 2026, downgraded from a Hold rating. This reflects some underlying concerns regarding the stock’s fundamentals or valuation metrics. Cipla remains a large-cap stock with a market capitalisation of ₹1,05,133 crores, making it a key player in the Pharmaceuticals & Biotechnology sector.
Expiry Dynamics and Investor Strategy
With the 26 May expiry less than two weeks away, the concentration of call option trades at ₹1,300 and ₹1,400 strikes indicates that market participants are positioning for a potential rally above these levels. The higher open interest at the ₹1,400 strike suggests a stronger conviction that the stock could breach this price point, which would represent a gain of approximately 4.7% from the current underlying price.
Such positioning often reflects expectations of positive catalysts, possibly linked to upcoming earnings, regulatory approvals, or sectoral tailwinds. However, investors should remain cautious given the recent downgrade and the stock’s mixed technical signals.
Comparative Sector and Benchmark Performance
On the day of the reported activity, Cipla’s 4.56% return significantly outpaced the Pharmaceuticals & Biotechnology sector’s 0.67% gain and the broader Sensex’s 0.63% rise. This relative outperformance highlights Cipla’s renewed investor focus and may explain the surge in call option volumes as traders seek leveraged exposure to the stock’s upside potential.
Liquidity and Trading Viability
The stock’s liquidity remains robust, with a traded value sufficient to support sizeable trades up to ₹3.88 crores based on 2% of the five-day average traded value. This ensures that both equity and derivatives traders can execute positions with minimal slippage, an important consideration for institutional investors and high-frequency traders alike.
Outlook and Considerations for Investors
While the surge in call option activity signals bullish sentiment, Cipla’s current Mojo Sell rating and mixed technical indicators counsel prudence. Investors should weigh the potential for near-term gains against the backdrop of fundamental concerns and broader market conditions. Monitoring upcoming corporate announcements and sector developments will be crucial in assessing whether the bullish positioning in options translates into sustained equity gains.
In summary, Cipla Ltd’s active call option market ahead of the May expiry reflects a market expectation of positive price movement, supported by recent price rebounds and increased investor participation. However, the stock’s longer-term momentum and fundamental outlook remain under scrutiny, making it essential for investors to adopt a balanced and well-informed approach.
